Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin

Molecular and Cellular Biology

Volumn 22, Issue 20, 2002, Pages 7004-7014

  Hudson, Christine C ^a   Liu, Mei ^a   Chiang, Gary G ^a   Otterness, Diane M ^a   Loomis, Dawn C ^a   Kaper, Fiona ^a   Giaccia, Amato J ^a   Abraham, Robert T ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RAPAMYCIN;

ARTICLE; CELL TYPE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL HYPOXIA; CHROMONES; COBALT; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GLUCOSE TRANSPORTER TYPE 1; HELIX-LOOP-HELIX MOTIFS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUPEPTINS; MONOSACCHARIDE TRANSPORT PROTEINS; MORPHOLINES; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 0036789574     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.22.20.7004-7014.2002     Document Type: Article

References (52)

1. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483-510.
2. Aoki, M., E. Blazek, and P. K. Vogt. 2001. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98:136-141.
3. Brizel, D. M., S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz, and M. W. Dewhirst. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941-943.
4. Brizel, D. M., G. S. Sibley, L. R. Prosnitz, R. L. Scher, and M. W. Dewhirst. 1997. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:285-289.
5. Bruick, R. K., and S. L. McKnight. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340.
6. Bruick, R. K., and S. L. McKnight. 2002. Transcription: oxygen sensing gets a second wind. Science 295:807-808.
7. Brunn, G. J., P. Fadden, T. A. J. Haystead, and J. C. Lawrence, Jr. 1997. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J. Biol. Chem. 272:32547-32550.
8. Brunn, G. J., C. C. Hudson, A. Sekulic, J. M. Williams, J. Hosoi, P. J. Houghton, J. C. Lawrence, and R. T. Abraham. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101.
9. Brunn, G. J., J. Williams, C. Sabers, G. Wiederrecht, J. C. Lawrence, Jr., and R. T. Abraham. 1996. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15:5256-5267.
10. Chen, E. Y., N. M. Mazure, J. A. Cooper, and A. J. Giaccia. 1915. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 61:2429-2433.
11. Chen, J., X. F. Zheng, E. J. Brown, and S. L. Schreiber. 1995. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA 92:4947-4951.
12. Di Cristofano, A., and P. P. Pandolfi. 2000. The multiple roles of PTEN in tumor suppression. Cell 100:387-390.
13. Dilling, M. B., P. Dias, D. N. Shapiro, G. S. Germain, R. K. Johnson, and P. J. Houghton. 1994. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 54:903-907.
14. Ebert, B. L., J. D. Firth, and P. J. Ratcliffe. 1995. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J. Biol. Chem. 270:29083-29089.
15. Epstein, A. C. R., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54.
16. Gingras, A. C., B. Raught, and N. Sonenberg. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:807-826.
17. Hirota, K., and G. L. Semenza. 2001. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J. Biol. Chem. 276:21166-21172.
18. Hockel, M., and P. Vaupel. 2001. Biological consequences of tumor hypoxia. Semin. Oncol. 28:36-41.
19. Holmgren, L. 1996. Antiangiogenis restricted tumor dormancy. Cancer Met. Rev. 15:241-245.
20. Ivan, M., and W. G. J. Kaelin. 2001. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Gen. Dev. 11:27-34.
21. Ivan, M., K. Kondo, H. F. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin. 2001. HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O-2 sensing. Science 292:464-468.
22. 2-regulated prolyl hydroxylation. Science 292:468-472.
23. Jiang, B. H., G. Q. Jiang, J. Z. Zheng, Z. M. Lu, T. Hunter, and P. K. Vogt. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor. Cell Growth Differ. 12:363-369.
24. Klippel, A., M. A. Escobedo, M. S. Wachowicz, G. Apell, T. W. Brown, M. A. Giedlin, W. M. Kavanaugh, and L. T. Williams. 1998. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol. 18:5699-5711.
25. Lando, D., D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L Whitelaw. 2002. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 295:858-861.
26. Laughner, E., P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:3995-4004.
27. Masson, N., C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:5197-5206.
28. Maxwell, P. H., C. W. Pugh, and P. J. Ratcliffe. 2001. Activation of the HIF pathway in cancer. Curr. Opin. Gen. Dev. 11:293-299.
29. Mazure, N. M., E. Y. Chen, K. R. Laderoute, and A. J. Giaccia. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322-3331.
30. Mills, G. B., Y. Lu, and E. C. Kohn. 2001. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:10031-10033.
31. Nakatani, K., D. A. Thompson, A. Barthel, H. Sakaue, W. Liu, R. J. Weigel, and R. A. Roth. 1999. Upregulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 274:21528-21532.
32. Nave, B. T., D. M. Ouwens, D. J. Withers, D. R. Alessi, and P. R. Shepherd. 1999. Mammalian target of rapamycin is a direct target for PKB: identification of a convergence point for opposing effects of insulin and amino acid deficiency on protein translation. Biochem. J. 344:427-431.
33. Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10314-10319.
34. 1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. 8:1487-1503.
35. Podsypanina, K., R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten(+/-) mice. Proc. Natl. Acad. Sci. USA 98:10320-10325.
36. Powis, G., R. Bonjouklian, M. M. Berggren, A. Gallegos, R. Abraham, C. Ashendel, L. Zalkow, W. F. Matter, J. Dodge, and G. Grindey. 1994. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 54:2419-2423.
37. Rohde, J., J. Heitman, and M. E. Cardenas. 2001. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276:9583-9586.
38. Sekulic, A., C. C. Hudson, J. L. Homme, P. Yin, D. M. Otterness, L. M. Karnitz, and R. T. Abraham. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60: 3504-3513.
39. Semenza, G. L. 2000. HIF-1 and human disease: one highly involved factor. Genes Dev. 14:1983-1991.
40. Semenza, G. L. 2001. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13:167-171.
41. Semenza, G. L. 2001. HIF-1, O-2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1-3.
42. Semenza, G. L. 2000. HIF-1: using two hands to flip the angiogenic switch. Cancer Met. Rev. 19:59-65.
43. Semenza, G. L. 1999. Regulation of mammalian O-2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:551-578.
44. Sutter, C. H., E. Laughner, and G. L. Semenza. 2000. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA 97:4748-4753.
45. Talks, K. L., H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. L. Harris. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411-421.
46. Ting, A. T., C. J. Dick, R. A. Schoon, L. M. Karnitz, R. T. Abraham, and P. J. Leibson. 1995. Interaction between Lck and Syk family tyrosine kinases in Fc gamma receptor-initiated activation of natural killer cells. J. Biol. Chem. 270:16415-16421.
47. Yang, H. F., and W. G. Kaelin. 2001. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 12:447-455.
48. Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630-9635.
49. Zagzag, D., H. Zhong, J. M. Scalzitti, E. Laughner, J. W. Simons, and G. L. Semenza. 2000. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618.
50. Zhong, H., K. Chiles, D. Feldser, E. Langhner, C. Hanrahan, M. M. Georgescu, J. W. Simons, and G. L. Semenza. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541-1545.
51. Zhong, H., M. De, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza, and J. W. Simons. 1999. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:5830-5835.
52. Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A. R. Gottschalk, H. E. Ryan, R. S. Johnson, A. B. Jefferson, D. Stokoe, and A. J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:391-396.